Soligenix (NASDAQ:SNGX) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Soligenix (NASDAQ:SNGX) announced its quarterly earnings data on Friday. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19), Zacks reports. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.20 million. During the same period in the previous year, the firm posted ($12.66) earnings per share.

Soligenix Stock Up 0.4 %

Soligenix stock opened at $2.39 on Friday. Soligenix has a 12 month low of $1.83 and a 12 month high of $14.92. The stock has a market cap of $6.00 million, a P/E ratio of -0.32 and a beta of 2.03. The company’s fifty day simple moving average is $2.37 and its 200-day simple moving average is $3.12.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.